PRS44 Cost-Effectiveness Analysis of Umeclidinium Bromide Compared to Tiotropium Bromide for Symptomatic Patients with COPD in the UK  by Ismaila, A. et al.
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 3 2 3 – A 6 8 6  A595
over a 10-year horizon. A National Health Service (NHS) and personal social ser-
vices perspective was considered. The effectiveness of treatment was evaluated 
in terms of Quality Adjusted Life Years (QALYs) and Disability Adjusted Life Years 
(DALYs). Data were sourced from a phase II, placebo controlled trial of bedaquiline, 
NHS reference costs, and the literature. Costs and effectiveness were discounted 
at a rate of 3.5% per annum. Probabilistic and deterministic sensitivity analysis 
was conducted. Results: The total discounted cost per patient on B+BR was 
£107,123, compared with £116,616 for BR. The total discounted QALYs per patient 
were 4.85 for B+BR and 3.81 for BR. The addition of bedaquiline to BR resulted 
in cost-savings of £9,493 and an additional 1.04 QALYs pp over a 10-year period, 
and is therefore considered to be the dominant (less costly and more effective) 
strategy over BR. B+BR remained dominant versus BR in the majority of sensitivity 
analyses, with a 74% probability of being dominant versus BR in the probabilistic 
analysis. ConClusions: In the UK, bedaquiline is likely to be cost-effective and 
cost-saving, compared to the current standard of care for MDR-TB under a range 
of scenarios. Cost-savings over a 10 year period were realized from reductions in 
lengths of hospital stay, which offset bedaquiline drug costs. Bedaquiline remained 
cost-saving in several sensitivity analyses, highlighting the certainty surrounding 
the results of the model. These results also indicate that the B+BR regimen can 
provide significant social economic benefits versus the BR only regimen.
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objeCtives: To evaluate the long-term cost-effectiveness of umeclidinium bromide 
62.5 mcg OD (UMEC) compared to tiotropium bromide 18 mcg OD (TIO) for the 
maintenance treatment of COPD from the UK National Health Service perspec-
tive Methods: We utilized a recently developed, internally and externally validated 
linked equations COPD Cohort disease progression model. The treatment effect, 
expressed as change from baseline in forced expiratory volume in one second (FEV1) 
at 12 and 24 weeks estimated from a Bucher method indirect treatment comparison 
(ITC) analysis following a systematic review. UMEC price was set at parity price of 
£33.5/month to TIO. Model outcomes included exacerbations, life years, quality 
adjusted life years (QALYs) and costs/QALY. The time horizons investigated ranged 
from one to 20 years (lifetime) on a sliding one-year increment. Costs, survival, and 
QALYs after the first year were discounted at a rate of 3.5%. Health care costs were 
obtained from NHS reference costs (2011-12). Sensitivity analyses were performed 
to evaluate the robustness of the model to variations in the underlying input param-
eters and assumptions. Results: The ITC estimated change from baseline in trough 
FEV1 of 18.06mL (95%CI: -19.11, 55.23, p= 0.341) at 12 weeks and 3.97mL (95%CI: 
-38.30, 46.25, p= 0.854) at 24 weeks for UMEC compared with TIO. At price parity, 
UMEC dominated TIO with incremental QALY of 0.0009, incremental life years of 
0.0001 and cost reduction of £4.54. The sensitivity analyses suggested that variation 
in main parameters will not alter the behavior of the comparison between the two 
treatments. ConClusions: At price parity to TIO, UMEC may be considered as a 
cost-effective treatment alternative for maintenance bronchodilator treatment to 
relieve symptoms in patients with COPD in the UK.
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objeCtives: UMEC/VI is a long acting muscarinic agent (LAMA) and long acting beta 
agonist (LABA) combination therapy. This study evaluated the cost-effectiveness of 
UMEC/VI compared to tiotropium (18µg) from the UK National Health Service per-
spective. Methods: A linked equations cohort model developed using the patient 
level data from ECLIPSE study and validated using patient level data from TORCH 
study was used. The baseline patient characteristics were derived from UMEC/VI 
phase IIIa clinical programme and included symptomatic COPD patients. The treat-
ment effect expressed as change from baseline in forced expiratory volume in one 
second (FEV1) at 24 weeks was estimated using 3 tiotropium comparator phase 
IIIa trials and was assumed to last for at least 52 weeks following treatment initia-
tion. Model outcomes included exacerbations, life years, quality adjusted life years 
(QALYs) and costs/QALY. The timeframe for the analysis was patient lifetime and the 
discount rate for costs and outcomes was 3.5%. The price of UMEC/VI was varied to 
estimate the points at which it would be cost effective compared with the current 
standard of care tiotropium. Health care costs were obtained from NHS reference 
costs (2011-12). Results: The random effects meta-analysis estimated treatment 
benefit of 92.17ml (95% CI: 61.52, 122.82; p< 0.001) in FEV1for UMEC/VI compared with 
tiotropium. A lifetime model resulted in 0.009 fewer moderate-severe exacerbations 
per year on UMEC/VI. At parity price (£33.5/month), UMEC/VI dominated tiotro-
pium with a probability of 0.81 for being cost effective at £30,000/QALY threshold. 
The incremental cost effectiveness ratios were £11,080 and £22,178 at 5% and 10% 
price premium to tiotropium, respectively. ConClusions: At an appropriate price, 
UMEC/VI may be considered as a cost-effective treatment alternative for sympto-
matic patients with COPD.
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and severe exacerbations were also evaluated and the costs were set for one single 
event. Results: The total cost of mild COPD was € 26.22, moderate COPD € 30.26, 
severe COPD € 92.04 and for the very severe COPD € 267.64 for 1 patient/3 months. 
Expenses for bronchodilators also vary between different stages of COPD, for mild 
COPD it represented € 17.44, moderate COPD € 109.54, severe COPD € 219.58 and for 
very severe COPD € 206.15. Cost of treating exacerbations were set for one event - for 
moderate exacerbation € 67 and for severe exacerbation € 1060.27. ConClusions: 
In the management of COPD the most expensive are the costs of hospitalization, 
outpatient care and symptomatic treatment. The most costly is the management 
of the very severe COPD and severe exacerbation. This survey can be used as the 
source for cost inputs in pharmacoeconomic studies.
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objeCtives: The objective was to analyze the cost-effectiveness of a national immu-
nization program with pneumococcal conjugate vaccine (PCV): 10-valent pneumo-
coccal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) 
and 13-valent pneumococcal conjugate vaccine (PCV-13) in Romania. Methods: A 
published age stratified, deterministic, and static cohort model is used. This model 
highlights changes in cost and quality adjusted life years (QALYs) over time. Serotype 
specific disease incidence, age stratified disease incidence, mortality in the popu-
lation, vaccine costs and resource utilization costs were obtained from a General 
Practitioner reports database and epidemiological sources. The model compared 
identical immunization programs involving PHiD-CV and PCV-13 vaccines taking the 
payer perspective. A cohort of 201,104 Romanian infants was followed for four years. 
Same net indirect protection for invasive pneumococcal disease (IPD) was assumed 
for both vaccines. Results: With 80% vaccine uptake and 2+1 vaccination schedule, 
PHiD-CV dominated PCV-13 assuming price parity. Vaccination with PHiD-CV versus 
PCV-13 resulted in an offset for the health care budget of £22,948 (the main driver 
of this difference is the decrease in Acute Otitis Media (AOM) related costs – with a 
total of 4,663 cases prevented) and a total of 23 QALYs gained. Sensitivity analyses 
revealed robustness of the model results, confirmed the dominance of PHiD-CV 
over PCV-13 and substantiated model outcome driven by incremental efficacy of 
PHiD-CV in conjunction with high incidence AOM. ConClusions: According to the 
model, implementation of PHiD-CV vaccination program for infants in Romania will 
offer substantial benefits in terms of cost savings and improved health compared 
to an identical vaccination program involving PCV-13. PHiD-CV’s potential to better 
prevent AOM translates into incremental benefits and dominance of PHiD-CV over 
PCV-13 given that their impact on IPD is similar.
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objeCtives: Disease management programs for chronic obstructive pulmonary 
disease (herein, COPD-DM) are currently implemented on a broad scale in the 
Netherlands. However, the evidence about their cost-effectiveness is still inconclusive. 
We aimed to conduct a cost-effectiveness analysis of a COPD-DM program in primary 
care in the Netherlands, called RECODE. In RECODE, a multidisciplinary primary care 
team was trained in motivational interviewing to improve life style, setting-up indi-
vidual care plans, early recognizing and managing of exacerbations, and implement-
ing clinical guidelines. In addition, clinical decision making was supported by audit 
and feedback reports provided by an ICT program and reimbursement of physical 
reactivation by a physiotherapist was provided. Methods: In a two-year cluster-ran-
domized controlled trial (1086 COPD patients, 40 clusters), the COPD-DM program was 
compared to usual care. As part of this trial we conducted a cost-effectiveness analysis 
to relate the effect of the COPD-DM on intermediate and final health outcomes to the 
costs from a health care and a societal perspective. Detailed self-reported health care 
utilization data were collected during the trial-period. Results: The 2-year inter-
vention costs of the training for professionals, the ICT, and the audit and feedback 
reports were estimated to be € 324 per patient. Excluding these costs, the intervention 
group had € 584 (95% CI € 86 to € 1,046) higher health care costs and € 645 (95% CI € 28 to 
€ 1,190) higher costs from the societal perspective compared to the usual care group. 
Health outcomes were similar in both groups, except for 0.04 (95% CI -0.07 to -0.01) 
less quality-adjusted life-years in the intervention group. ConClusions: RECODE 
was not cost-effective during the 2-year follow-up period. This is most likely due to 
the fact that the interventions targeted professionals instead of patients and were 
suboptimally implemented, the relatively mild COPD population, and the national 
reforms in COPD care that affected the usual care group.
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objeCtives: To evaluate the cost-effectiveness of adding bedaquiline to the inten-
sive phase of background regimens (BR) of drugs for multidrug-resistant tuberculosis 
(MDR-TB) in the United Kingdom (UK). Methods: A cohort-based Markov model 
was developed to estimate the incremental cost-effectiveness ratio of bedaqui-
line plus BR (B+BR) versus BR alone (BR) in the treatment of MDR-TB in the UK, 
